TX-STATLAB
StatLab Medical Products (“StatLab”), a leading global developer and manufacturer of medical diagnostic supplies and equipment, today announced that it has reached an agreement to acquire Diapath S.p.A. (“Diapath”), a prominent Italian manufacturer of histology and cytology products and equipment. The integration of Diapath, with its highly innovative equipment offerings, manufacturing capabilities, and established customer base across Europe, Asia-Pacific, Middle East and Africa, and Latin America, positions StatLab to expand its market access, unlocking significant potential for growth and enhancing its global leadership.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240828096902/en/
Diapath’s equipment portfolio, which includes tissue processors, stainers, embedding centers, and microtomes, is underpinned by its innovative development process and cutting-edge Italian design and quality, resulting in a differentiated product set that resonates with customers. (Photo: Business Wire)
The transaction is expected to close during the third quarter of 2024, subject to regulatory approvals. Upon closing, Diapath founder Vladimiro Bergamini will transition to a senior advisor role at StatLab, and Chief Operating Officer Alberto Battistel will join StatLab’s executive leadership team and help steer the Diapath business unit as its Managing Director.
“This combination is a pivotal milestone in our strategy to manufacture the full array of products supporting the entire anatomic pathology workflow,” said Sung-Dae Hong, CEO of StatLab. “Our partnership with Diapath will provide an opportunity to expand their equipment brand throughout global markets, including the U.S. The combination will also enhance StatLab’s European market access for slides, cassettes, and printers, driving our product innovation and manufacturing excellence to the next level. I’m excited to welcome Alberto and the talented Diapath team to StatLab and continue to build upon the legacy Vladimiro and his family have developed over the past three decades.”
Headquartered in Martinengo, near Bergamo, Italy, Diapath was founded in 1997 by Vladimiro Bergamini. Over the past 27 years, focused investments have enabled the business to expand beyond consumables manufacturing and into the design, development, and production of a variety of core histology instruments.
Diapath’s equipment portfolio, which includes tissue processors, stainers, embedding centers, and microtomes, is underpinned by its innovative development process and cutting-edge Italian design and quality, resulting in a differentiated product set that resonates with customers. The Diapath Donatello automatic tissue processor won a prestigious A’Design Award for Scientific Instruments, and the T-Filler Automatic Formalin dispenser protects technicians from chemical exposure while ensuring specimens receive the correct ratio of formalin. In addition to their strong Italian presence, Diapath’s subsidiaries support focused growth of Diapath products to laboratories in Germany and France.
“The decision to join StatLab is driven by our shared commitment to growth and innovation to meet customer needs,” said Vladimiro Bergamini, CEO & President of Diapath. “Our combined company will be uniquely positioned to further expand Diapath’s brand and business, together transforming the anatomic pathology market through innovative development and manufacturing. I’m looking forward to the work my team will do with Dae and StatLab to leverage our combined global manufacturing capabilities to capture new business opportunities.”
About StatLab Medical Products
StatLab Medical Products has been dedicated to helping anatomic pathology laboratories provide the best possible patient care since 1976. We offer an extensive portfolio of self-manufactured consumables and labeling and tracking equipment from eight manufacturing sites in the United States, United Kingdom, and Germany. Our global operational footprint powered by over 600 mission-driven colleagues delivers a dependable and resilient supply chain of high-quality products and solutions, and a customer-centric approach inspires us to deliver reliability, innovation, and quality in every interaction. Learn more at StatLab.com.
About Diapath
Diapath is a leading Italian company specializing in the design, development, and manufacturing of advanced histology and cytology instruments and consumables. With nearly three decades of experience, Diapath is committed to innovation and excellence, offering cutting-edge solutions that redefine laboratory processes to ensure increasingly reliable diagnostics for better cancer care. Our products, distinguished by their Italian design and quality, range from processors and stainers to embedding centers and more, supporting the entire anatomic pathology workflow. Dedicated to enhancing histological research and diagnostics, Diapath continues to set industry standards with a focus on quality and innovation. Learn more at Diapath.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240828096902/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
87% of Institutional Investors Have Declined or Reconsidered Fund Commitments Due to AML/KYC Concerns17.11.2025 14:30:00 CET | Press release
63% of GPs say they have lost investors or reinvestments due to AML/KYC compliance shortcomings88% of LPs are more likely to invest in a manager with a formal AML/KYC programNearly three-quarters of GPs report cost savings of 10-30% from outsourcing AML/KYC functions to dedicated specialists Nearly nine-in-10 (87%) limited partners (LPs) have declined or reconsidered a fund allocation due to anti-money laundering and Know Your Customer (AML/KYC) concerns, underscoring just how significant compliance has become as a gatekeeping item for fundraising. According to a new study by CSC, the leading provider of global business administration and compliance solutions, general partners (GPs) are already feeling the strain. Almost two-thirds (63%) report losing investors or reinvestments due to AML/KYC shortcomings, most commonly from documentation gaps (61%) and onboarding delays (24%). CSC surveyed 200 GPs and 200 LPs across North America, Europe, the U.K., and Asia Pacific to capture views on
Cardano Summit 2025 Concludes In Berlin: Trust Emerges As The Winner with Traditional Financial Firms Feeling Blockchain FOMO17.11.2025 14:23:00 CET | Press release
Cardano Foundation Highlights Ambitious Growth Roadmap and Announces Singapore for 2026 Event Last week’s Cardano Summit 2025 at Berlin’s iconic Gasometer heard from 140 speakers, brought together close to 800 attendees from over 70 countries, and attracted over 25,000 online participants, showcasing significant momentum in enterprise blockchain adoption. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117496852/en/ Cardano Foundation CEO Frederik Gregaard on the main stage at the Cardano Summit 2025 in Berlin Across two days of strategic discussions, enterprise leaders joined the Cardano community to discuss industry readiness, DeFi expansion, and the convergence of AI with distributed systems. The Cardano Foundation also outlined its 2026 roadmap highlighting decentralized finance (DeFi) liquidity, Web3 integration, and real-world asset (RWA) tokenization as key focus areas. Additionally, Singapore was unveiled as the lo
MUSASHI JAPAN by TAIMATSU Launches “Dual Blades” – A Black Friday Experience Redefining Luxury Craftsmanship17.11.2025 14:11:00 CET | Press release
MUSASHI JAPAN by TAIMATSU, a contemporary Japanese knife brand rooted in the spirit of craftsmanship and cultural harmony, announces its 2025 Black Friday campaign: “Dual Blades.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117626760/en/ This year, MUSASHI moves beyond traditional discount culture to celebrate the philosophy of balance, precision, and mastery. Inspired by the concept of Nitōryu — the dual-blade technique symbolizing harmony between strength and grace — the campaign invites customers to experience the unity and balance of two blades. What begins as a Black Friday promotion becomes an artistic expression of Japanese craftsmanship. At Musashi Japan, we extend the history and philosophy of Nitōryu into the modern kitchen, guiding customers toward the ideal combination of knives for their everyday cooking. Not everything can—or should—be cut with a single knife. Each ingredient deserves the blade designed f
Riskified Champions Fraud Prevention as a Leading Partner of International Fraud Awareness Week 202517.11.2025 14:00:00 CET | Press release
During the critical holiday shopping season, Riskified calls for greater ecommerce safety to maintain consumer trust Riskified (NYSE: RSKD), a global leader in ecommerce fraud prevention and risk intelligence, announces its participation in International Fraud Awareness Week, taking place November 16–22, 2025. Joining hundreds of organizations worldwide, Riskified aims to raise awareness about the urgent need to fight fraud and help safeguard merchants and their customers globally, especially as online shopping heats up ahead of the holidays. Deloitte forecasts holiday ecommerce sales of $305–$311 billion in 2025, bringing a wave of new and returning customers and incremental revenue to businesses. Unfortunately, this growth also presents fraudsters with an enticing opportunity: losses from ecommerce fraud are projected to reach $107 billion by 2029, according to Juniper Research. AI is reshaping both shopping behavior and criminal tactics at unprecedented speed. Riskified data shows t
MSCI Announces Baer Pettit to Retire as President17.11.2025 13:00:00 CET | Press release
Additional senior leadership changes will drive growth in new client segments and products MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced that C.D. Baer Pettit, President and Chief Operating Officer (COO), and a member of the Board of Directors, has informed the company that he will retire next year after more than 25 years in senior leadership roles. Mr. Pettit will continue to serve as President and a Director until March 1, 2026, and will remain as an advisor to the company for a period of time to ensure a smooth transition. Mr. Pettit joined MSCI in 2000 and has served in numerous senior leadership roles, including heading Client Coverage, Marketing and Index. He was appointed COO in 2015 and President in 2017, overseeing all products and operations, and he joined the Board of Directors in 2023. “Baer has been my longtime business partner, and he has played a pivotal role in shaping MSCI’s st
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom